PL377708A1 - Oksazole jako wzmacniacze mGluR1 - Google Patents
Oksazole jako wzmacniacze mGluR1Info
- Publication number
- PL377708A1 PL377708A1 PL377708A PL37770803A PL377708A1 PL 377708 A1 PL377708 A1 PL 377708A1 PL 377708 A PL377708 A PL 377708A PL 37770803 A PL37770803 A PL 37770803A PL 377708 A1 PL377708 A1 PL 377708A1
- Authority
- PL
- Poland
- Prior art keywords
- mglur1
- oxazoles
- enhancer
- mglur1 enhancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- AIDS & HIV (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02028747 | 2002-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL377708A1 true PL377708A1 (pl) | 2006-02-06 |
| PL211061B1 PL211061B1 (pl) | 2012-04-30 |
Family
ID=32668736
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL377708A PL211061B1 (pl) | 2002-12-23 | 2003-12-17 | Pochodne oksazolu, sposób ich wytwarzania, ich zastosowanie i kompozycja farmaceutyczna |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7119113B2 (pl) |
| EP (1) | EP1578746B1 (pl) |
| JP (1) | JP4286788B2 (pl) |
| KR (1) | KR100713265B1 (pl) |
| CN (1) | CN100336813C (pl) |
| AR (1) | AR042643A1 (pl) |
| AT (1) | ATE329913T1 (pl) |
| AU (1) | AU2003298195B8 (pl) |
| BR (1) | BR0317714A (pl) |
| CA (1) | CA2511337C (pl) |
| DE (1) | DE60306202T2 (pl) |
| ES (1) | ES2265600T3 (pl) |
| MX (1) | MXPA05006657A (pl) |
| PL (1) | PL211061B1 (pl) |
| RU (1) | RU2345076C2 (pl) |
| WO (1) | WO2004056814A1 (pl) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016267A2 (en) * | 2003-08-06 | 2005-02-24 | Pfizer Products Inc. | Oxazole compounds for the treatment of neurodegenerative disorders |
| AR057218A1 (es) | 2005-12-15 | 2007-11-21 | Astra Ab | Compuestos de oxazolidinona y su uso como pontenciadores del receptor metabotropico de glutamato |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| WO2009098455A1 (en) * | 2008-02-06 | 2009-08-13 | Astrazeneca Ab | 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease |
| CN103319447B (zh) * | 2013-06-18 | 2015-05-20 | 烟台万润精细化工股份有限公司 | 一种呫吨-9-羧酸的制备方法 |
| US20210161910A1 (en) * | 2019-12-02 | 2021-06-03 | University Of Connecticut | Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6803381B1 (en) * | 1999-04-20 | 2004-10-12 | Hoffmann-La Roche Inc. | Carbamic acid derivatives |
| TW593241B (en) * | 1999-04-20 | 2004-06-21 | Hoffmann La Roche | Carbamic acid derivatives |
-
2003
- 2003-12-17 AU AU2003298195A patent/AU2003298195B8/en not_active Ceased
- 2003-12-17 ES ES03795907T patent/ES2265600T3/es not_active Expired - Lifetime
- 2003-12-17 CA CA2511337A patent/CA2511337C/en not_active Expired - Fee Related
- 2003-12-17 JP JP2004561328A patent/JP4286788B2/ja not_active Expired - Fee Related
- 2003-12-17 BR BR0317714-9A patent/BR0317714A/pt not_active IP Right Cessation
- 2003-12-17 PL PL377708A patent/PL211061B1/pl unknown
- 2003-12-17 WO PCT/EP2003/014395 patent/WO2004056814A1/en active IP Right Grant
- 2003-12-17 RU RU2005123328/04A patent/RU2345076C2/ru not_active IP Right Cessation
- 2003-12-17 CN CNB2003801072986A patent/CN100336813C/zh not_active Expired - Fee Related
- 2003-12-17 EP EP03795907A patent/EP1578746B1/en not_active Expired - Lifetime
- 2003-12-17 DE DE60306202T patent/DE60306202T2/de not_active Expired - Lifetime
- 2003-12-17 MX MXPA05006657A patent/MXPA05006657A/es active IP Right Grant
- 2003-12-17 KR KR1020057011724A patent/KR100713265B1/ko not_active IP Right Cessation
- 2003-12-17 AT AT03795907T patent/ATE329913T1/de active
- 2003-12-18 US US10/740,245 patent/US7119113B2/en not_active Expired - Fee Related
- 2003-12-22 AR ARP030104765A patent/AR042643A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1578746B1 (en) | 2006-06-14 |
| AU2003298195A1 (en) | 2004-07-14 |
| RU2005123328A (ru) | 2006-02-27 |
| AR042643A1 (es) | 2005-06-29 |
| AU2003298195B8 (en) | 2009-04-23 |
| US7119113B2 (en) | 2006-10-10 |
| WO2004056814A1 (en) | 2004-07-08 |
| MXPA05006657A (es) | 2005-08-16 |
| RU2345076C2 (ru) | 2009-01-27 |
| BR0317714A (pt) | 2005-11-22 |
| EP1578746A1 (en) | 2005-09-28 |
| PL211061B1 (pl) | 2012-04-30 |
| CA2511337C (en) | 2011-12-20 |
| CA2511337A1 (en) | 2004-07-08 |
| ATE329913T1 (de) | 2006-07-15 |
| JP2006512343A (ja) | 2006-04-13 |
| AU2003298195B2 (en) | 2009-04-02 |
| CN1735610A (zh) | 2006-02-15 |
| US20040132792A1 (en) | 2004-07-08 |
| KR100713265B1 (ko) | 2007-05-04 |
| CN100336813C (zh) | 2007-09-12 |
| ES2265600T3 (es) | 2007-02-16 |
| KR20050087848A (ko) | 2005-08-31 |
| JP4286788B2 (ja) | 2009-07-01 |
| DE60306202T2 (de) | 2007-06-06 |
| DE60306202D1 (de) | 2006-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003299034A8 (en) | Transdermal compositions | |
| EG24528A (en) | Herbicidal composition | |
| IL166624A0 (en) | Taxane derivatives | |
| GB0220467D0 (en) | Composition | |
| GB0213638D0 (en) | Composition | |
| HRP20030625A2 (en) | Herbicidal composition | |
| PL377087A1 (pl) | Związki heterocykliczne | |
| EP1531670A4 (en) | HERBICIDE COMPOSITION | |
| IL166478A0 (en) | Bicifadine formulation | |
| GB0318894D0 (en) | Composition | |
| EP1542696A4 (en) | OXAZOLIDINONE DERIVATIVES AS ANTIMICROBIAL AGENTS | |
| GB0203421D0 (en) | Composition | |
| PL377519A1 (pl) | Związki N-(indoloetylo-)cykloaminowe | |
| GB0227244D0 (en) | Composition | |
| EP1476425A4 (en) | Heterocyclic Aryl Sulphonamidocyclic Compounds | |
| GB0208608D0 (en) | Composition | |
| GB0203280D0 (en) | Anti-glycolytic composition | |
| PL377708A1 (pl) | Oksazole jako wzmacniacze mGluR1 | |
| GB0211924D0 (en) | Composition | |
| GB0218241D0 (en) | Composition | |
| GB0318152D0 (en) | Composition | |
| HK1082517A1 (en) | Oil-barrier composition | |
| EP1495751A4 (en) | hair dye | |
| GB0229286D0 (en) | Composition | |
| PL372654A1 (pl) | Kompozycja chwastobójcza |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RECP | Rectifications of patent specification |